Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Impact of Immunoproteasome Inhibition in Preclinical Studies of Hemophagocytic Lymphohistiocytosis

Camille Keenan, Sabrin Albeituni, Alexa Stroh, Heather Tillman, Janet Anderl, Christopher J. Kirk, Kim E. Nichols

Blood (2022) 140 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2022-166779

Published: 2022

Journal Articles

Proteomic Profiling and Mechanistic Investigating of a Novel Anti-Cancer Small Molecule Inhibitor of Sec61

Yu Qian, PhD, Henry W.B. Johnson, PhD, Christopher J. Kirk, PhD, Eric Lowe, BS, Dustin McMinn, PhD, Beatriz Millare, BS, Tony Muchamuel, MS, Jinhai Wang, PhD

Blood (2019) 134 (Supplement_1): 2076.

https://doi.org/10.1182/blood-2019-125988

Published: 2019

Journal Articles

Blocking Protein Secretion with Novel Small Molecule Inhibitors of Sec61 Represents a Potential Treatment Strategy Against Hematologic Malignancies

Eric Lowe, BS, Andrea R Fan, PhD, Jing Jiang, Henry W. B. Johnson, PhD, Christopher J. Kirk, PhD, Dustin McMinn, PhD, Tony Muchamuel, MS, Yu Qian, PhD, Brian B. Tuch, PhD

Blood (2019) 134 (Supplement_1): 408.

https://doi.org/10.1182/blood-2019-123782

Published: 2019

Journal Articles

Protein Translocation Inhibitors Overcome Cytokine-Induced Glucocorticoid Resistance in T-Cell Acute Lymphoblastic Leukemia

Lauren K. Meyer, Cristina Delgado-Martin, PhD, Phillip P. Sharp, PhD, Dustin McMinn, PhD, Christopher J. Kirk, PhD, Jack Taunton, PhD, Michelle L. Hermiston, MD PhD

Blood (2019) 134 (Supplement_1): 805.

https://doi.org/10.1182/blood-2019-127537

Published: 2019

Journal Articles

Inhibition Of Autophagy By ACY-1215, a Selective HDAC6 Inhibitor Accelerates Carfilzomib-Induced Cell Death In Multiple Myeloma

Yuko Mishima, Loredana Santo, Diana D. Cirstea, Homare Eda, Neeharika Nemani, Shirin Arastu-Kapur, Ph.D, Christopher J. Kirk, Ph.D, Simon S Jones, PhD, Raje Noopur, MD

Blood (2013) 122 (21): 4431.

https://doi.org/10.1182/blood.V122.21.4431.4431

Published: 2013

Journal Articles

Blocking Protein Secretion and Degradation Is a Novel Treatment Strategy For Malignant Cells With High Protein Load

Eric Lowe, Rebecca Maglathlin, Alana Lerner, Ph.D, Jack Taunton, PhD, Christopher J. Kirk, Ph.D, Shirin Arastu-Kapur, Ph.D

Blood (2013) 122 (21): 4439.

https://doi.org/10.1182/blood.V122.21.4439.4439

Published: 2013

Journal Articles

Survival Pathways Stabilized By Proteasome Inhibition Reveal PIM2 As a Novel Target For Potentiating The Anti-Myeloma Activity Of Carfilzomib

Tracey Lin, B.S., Eric Lowe, B.S., Alana Lerner, Ph.D, Christopher J. Kirk, Ph.D, Shirin Arastu-Kapur, Ph.D

Blood (2013) 122 (21): 4440.

https://doi.org/10.1182/blood.V122.21.4440.4440

Published: 2013

Journal Articles

Immunoglobulin Expression Is a Major Determinant Of Patient Sensitivity To Proteasome Inhibitors

Brian B Tuch, Ph.D., Andrea Loehr, Ph.D., Jeremiah D Degenhardt, Ph.D., Kevin A Kwei, PhD, Jonathan J Keats, PhD, Christopher J. Kirk, Ph.D

Blood (2013) 122 (21): 1903.

https://doi.org/10.1182/blood.V122.21.1903.1903

Published: 2013

Journal Articles

Inhibition Of The Immunoproteasome Subunit LMP7 Decreases Alloresponses In Both MHC-Mismatched and miHA-Disparate Murine Models Of Graft Versus Host Disease

Jennifer Matos, PhD, Zheng Yang, Eugenia Dziopa, Leah Dziopa, Christopher J. Kirk, Ph.D, Robert Korngold, PhD, Jenny Zilberberg, Ph.D.

Blood (2013) 122 (21): 4472.

https://doi.org/10.1182/blood.V122.21.4472.4472

Published: 2013

Journal Articles

The Novel Immunoproteasome Inhibitor PR-924: Anti-Leukemic Activity and Mechanisms Of Resistance

Denise Niewerth, MSc, Johan van Meerloo, MSc, Yehuda Assaraf, PhD, Gerrit Jansen, PhD, Tessa C Hendrickx, BSc, Christopher J. Kirk, Ph.D, Janet Anderl, MS, Sonja Zweegman, MD PhD, Jacqueline Cloos, PhD, Gertjan Kaspers, MD, PhD

Blood (2013) 122 (21): 3841.

https://doi.org/10.1182/blood.V122.21.3841.3841

Published: 2013

Journal Articles

A Method To Identify Copy Number Aberrations (CNAs) From Whole Exome Sequence (WES) Data and Its Application To Multiple Myeloma Cell Lines and Patient Samples

Jeremiah D Degenhardt, Ph.D., Kenneth B Hoehn, Kevin A Kwei, Ph.D., Jonathan J Keats, PhD, Christopher J. Kirk, PhD, Brian B Tuch, Ph.D.

Blood (2013) 122 (21): 4881.

https://doi.org/10.1182/blood.V122.21.4881.4881

Published: 2013

Journal Articles

Development Of Methods To Perform Next Generation Sequencing (NGS)-Based Genomics Studies On Multiple Myeloma Clinical Samples

Jonathan J Keats, PhD, Kevin A Kwei, PhD, Jeremiah D Degenhardt, Ph.D., Kristi Allen, BS, Christopher J. Kirk, Ph.D, Brian B Tuch, Ph.D.

Blood (2013) 122 (21): 5347.

https://doi.org/10.1182/blood.V122.21.5347.5347

Published: 2013

Journal Articles

Carfilzomib, a Second-Generation Proteasome Inhibitor, In Combination With The Btk Inhibitor Ibrutinib As a Novel Therapeutic Regimen For Treating Double Hit DLBCL

Erin M Dominici, Elyse R Lopez, Muychi T Vang, Archito T. Tamayo, MS, Zhishuo Ou, MD, Alex Rollo, Liang Zhang, MD, PhD, Jack Wang, Lauren M Strickland, Michael Wang, MD, Richard J. Ford, MD, PhD, Lan V Pham, PhD, Christopher J. Kirk, Ph.D

Blood (2013) 122 (21): 1834.

https://doi.org/10.1182/blood.V122.21.1834.1834

Published: 2013

Journal Articles

A Novel Bruton′s Tyrosine Kinase Inhibitor CC-292 In Combination With The Proteasome Inhibitor Carfilzomib Iimpacts Multiple Myeloma Bone Microenviroment With Resultant Anti-Myeloma Activity

Homare Eda, Loredana Santo, Diana D Cirstea, Andrew J Yee, Tyler A Scullen, Neeharika Nemani, Yuko Mishima, Shirin Arastu-Kapur, Erica Evans, Juswinder Singh, Christopher J Kirk, William F Westlin, Noopur S Raje

Blood (2013) 122 (21): 682.

https://doi.org/10.1182/blood.V122.21.682.682

Published: 2013

Journal Articles

Selective Inhibitor Of Nuclear Exports (SINE) KPT-330 In Combination With The Novel Proteasome Inhibitor Carfilzomib As a Novel Therapeutic Regimen For Treating Aggressive B-Cell Lymphomas

Elyse R Lopez, Erin M Dominici, Muychi T Vang, Archito T. Tamayo, MS, Zhishuo Ou, MD, Alex Rollo, Liang Zhang, MD, PhD, Jack Wang, Lauren M Strickland, Christopher J. Kirk, Ph.D, Michael Kauffman, MD, PhD, Sharon Shacham, PhD, MBA, Michael Wang, MD, Lan V Pham, PhD, Richard J. Ford, MD, PhD

Blood (2013) 122 (21): 5147.

https://doi.org/10.1182/blood.V122.21.5147.5147

Published: 2013

Journal Articles

Use of the Immunoproteasome Subunit LMP7 Inhibitor to Ameliorate Gvhd in an MHC-Matched miHA-Disparate Murine Model

Jenny Zilberberg, Ph.D., Eugenia Dziopa, Christopher J Kirk, PhD, Robert Korngold, PhD

Blood (2012) 120 (21): 4106.

https://doi.org/10.1182/blood.V120.21.4106.4106

Published: 2012

Journal Articles

Interferon-γ-Induced Upregulation of Immunoproteasome Subunit Assembly Overcomes Bortezomib Resistance of Leukemia Cell Lines Harbouring Bortezomib-Induced Mutations in Constitutive PSMB5

Denise Niewerth, MSc, Niels Franke, MD, Gerrit Jansen, PhD, Yehuda Assaraf, PhD, Johan van Meerloo, MSc, Christopher J Kirk, PhD, Sonja Zweegman, MD, PhD, Gertjan J.L. Kaspers, MD, PhD, Jacqueline Cloos, PhD

Blood (2012) 120 (21): 1346.

https://doi.org/10.1182/blood.V120.21.1346.1346

Published: 2012

Journal Articles

Carfilzomib, An Irreversible Proteasome Inhibitor, Induces Long-Term Growth Inhibition of Mantle Cell Lymphoma In Vivo,

Liang Zhang, MD, PhD, Jianfei Qian, PhD, Zhishuo Ou, MD, Luhong Sun, MD, PhD, Kejie Zhang, MD, PhD, Lan V Pham, PhD, Christopher J Kirk, PhD, Richard J. Ford, MD, PhD, Qing Yi, MD, PhD, Michael Wang, MD

Blood (2011) 118 (21): 3740.

https://doi.org/10.1182/blood.V118.21.3740.3740

Published: 2011

Journal Articles

Potent Inhibition of Multiple Proteasome Subunits by Carfilzomib in Multiple Myeloma and Solid Tumor Patients

Susan J Lee, Tina M Woo, Shirin Arastu-Kapur, PhD, Alvin F Wong, Pharm.D., Thomas E Renau, PhD, Christopher J Kirk, PhD

Blood (2011) 118 (21): 5068.

https://doi.org/10.1182/blood.V118.21.5068.5068

Published: 2011

Journal Articles

Epoxyketone-Based Proteasome Inhibitors Carfilzomib and Orally Bioavailable ONX 0912 Have Anti-Resorptive and Bone-Anabolic Activity in Addition to Anti-Myeloma Effects

Michelle A Hurchla, Antonio Garcia-Gomez, Mary C Hornick, Enrique M Ocio, Aixiao Li, Juan F Blanco, Lynne Collins, Christopher J Kirk, David Piwnica-Worms, Ravi Vij, MD, Michael H Tomasson, Atanasio Pandiella, Jesús F San Miguel, Mercedes Garayoa, Katherine N Weilbaecher

Blood (2011) 118 (21): 2906.

https://doi.org/10.1182/blood.V118.21.2906.2906

Published: 2011

NARROW

Impact of Immunoproteasome Inhibition in Preclinical Studies of Hemophagocytic Lymphohistiocytosis

Proteomic Profiling and Mechanistic Investigating of a Novel Anti-Cancer Small Molecule Inhibitor of Sec61

Blocking Protein Secretion with Novel Small Molecule Inhibitors of Sec61 Represents a Potential Treatment Strategy Against Hematologic Malignancies

Protein Translocation Inhibitors Overcome Cytokine-Induced Glucocorticoid Resistance in T-Cell Acute Lymphoblastic Leukemia

Inhibition Of Autophagy By ACY-1215, a Selective HDAC6 Inhibitor Accelerates Carfilzomib-Induced Cell Death In Multiple Myeloma

Blocking Protein Secretion and Degradation Is a Novel Treatment Strategy For Malignant Cells With High Protein Load

Survival Pathways Stabilized By Proteasome Inhibition Reveal PIM2 As a Novel Target For Potentiating The Anti-Myeloma Activity Of Carfilzomib

Immunoglobulin Expression Is a Major Determinant Of Patient Sensitivity To Proteasome Inhibitors

Inhibition Of The Immunoproteasome Subunit LMP7 Decreases Alloresponses In Both MHC-Mismatched and miHA-Disparate Murine Models Of Graft Versus Host Disease

The Novel Immunoproteasome Inhibitor PR-924: Anti-Leukemic Activity and Mechanisms Of Resistance

A Method To Identify Copy Number Aberrations (CNAs) From Whole Exome Sequence (WES) Data and Its Application To Multiple Myeloma Cell Lines and Patient Samples

Development Of Methods To Perform Next Generation Sequencing (NGS)-Based Genomics Studies On Multiple Myeloma Clinical Samples

Carfilzomib, a Second-Generation Proteasome Inhibitor, In Combination With The Btk Inhibitor Ibrutinib As a Novel Therapeutic Regimen For Treating Double Hit DLBCL

A Novel Bruton′s Tyrosine Kinase Inhibitor CC-292 In Combination With The Proteasome Inhibitor Carfilzomib Iimpacts Multiple Myeloma Bone Microenviroment With Resultant Anti-Myeloma Activity

Selective Inhibitor Of Nuclear Exports (SINE) KPT-330 In Combination With The Novel Proteasome Inhibitor Carfilzomib As a Novel Therapeutic Regimen For Treating Aggressive B-Cell Lymphomas

Use of the Immunoproteasome Subunit LMP7 Inhibitor to Ameliorate Gvhd in an MHC-Matched miHA-Disparate Murine Model

Interferon-γ-Induced Upregulation of Immunoproteasome Subunit Assembly Overcomes Bortezomib Resistance of Leukemia Cell Lines Harbouring Bortezomib-Induced Mutations in Constitutive PSMB5

Carfilzomib, An Irreversible Proteasome Inhibitor, Induces Long-Term Growth Inhibition of Mantle Cell Lymphoma In Vivo,

Potent Inhibition of Multiple Proteasome Subunits by Carfilzomib in Multiple Myeloma and Solid Tumor Patients

Epoxyketone-Based Proteasome Inhibitors Carfilzomib and Orally Bioavailable ONX 0912 Have Anti-Resorptive and Bone-Anabolic Activity in Addition to Anti-Myeloma Effects

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only